ClinicalTrials.gg
CompletedNCT06529419LevanteUpdated Mar 2, 2026

A Dose Range-Finding Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD8630 in Adults With Uncontrolled Asthma at Risk of Exacerbations

A Phase 2 interventional study of AZD8630 and Placebo in Asthma, sponsored by AstraZeneca. Completed at 196 sites in 23 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-03-02.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
537
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 359 studies in Asthma by AstraZeneca — 19 open to participants now, 28 under way, 8 of them phase 3. Asthma · AstraZeneca.

Enrollment
67th of 248
537 · median 175
Started
2024
with 25 others
Phase 2
50 of 359
2 open now
Registered
330th of 359
by date

Among the 359 studies in Asthma by AstraZeneca, this one is the 67th largest by enrollment of the 248 interventional ones that give a count, is one of 26 that started in 2024, is one of 50 in phase 2, and was the 330th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

19 of the 359 studies in Asthma by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 19 open studies →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 359 studies in Asthma by AstraZeneca, or all of them as a file.
02

Study summary

A dose range-finding study to assess the efficacy and safety of multiple dose levels of AZD8630 administered via a dry powder inhaler in adults with uncontrolled asthma at risk of exacerbations, receiving medium -to -high dose inhaled corticosteroid (ICS)/long-acting β2-agonist (LABA).

Read the detailed description

This is a Phase II, randomised, placebo-controlled, double-blind, dose range-finding, multi-centre study to assess the efficacy and safety of inhaled AZD8630 administered at 3 doses via an inhaler in adult patients with uncontrolled asthma, at risk of an exacerbation. The study duration up to 57 weeks for participants in the optional safety extension study and up to 17 weeks for those not included. The maximal treatment period is up to 52 weeks.

This study will be conducted in approximately 220 centres in 20-25 countries. Approximately 516 patients will be randomised globally

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Principal inclusion criteria (abbreviated):

  1. Patient must be 18 to 80 years of age inclusive
  2. Documented physician diagnosis of asthma for at least 12 months, with objective evidence of asthma (spirometric, bronchial challenge, exercise challenge or therapeutic response) within the last 5 years

4. Uncontrolled asthma (i.e. ACQ-6 ≥ 1.5)

5. Pre-BD ≥ 40%

7. A history of asthma exacerbations within the last 12 months

8. \& 9. Compliant with asthma background mediation, daily ePROs and daily home spirometry.

10. within the range 18-37 kg/m2 (inclusive)

11. Female patients of child bearing potential must not be pregnant and agree to use highly effective .

12. Male patients and their female partners of must agree to use highly effective contraception.

13. Capable of giving signed .

Principal exclusion criteria (abbreviated):

  1. History of life-threatening asthma
  2. Recently completed treatment for respiratory infection and/or asthma exacerbation
  3. pulmonary disease other than asthma; including but not limited to those with co-existent .
  4. Any disorder that is not stable in the opinion of the Investigator and could:

    1. Affect the safety of the patient throughout the study
    2. Influence the findings of the study or their interpretation
    3. Impede the patient's ability to complete the entire duration of study
  5. Patients who, in the opinion of the Investigator, have evidence of active TB or are currently on treatment for active or latent TB.
  6. Medical history of or treatment for or , except for cured hepatitis C
  7. Patients with history of infection or who test positive for HIV.
  8. Congenital long syndrome or prolonged QTcF > 470 ms or history of QT prolongation associated with other medications that required discontinuation of that medication.
  9. Current untreated or uncontrolled arrhythmia.
  10. Patients with recent myocardial infarction, unstable angina pectoris, stroke, percutaneous coronary intervention or coronary artery bypass grafting.
  11. A helminth parasitic infection diagnosed that has not been treated, or has not responded to SoC therapy.
  12. Current smokers, former smokers with > 10 pack-years history, or former smokers who stopped smoking \< 6 months ago.
  13. Known history of drug or alcohol abuse within 12 months, that in the Investigator's opinion would preclude participation in the study.
  14. Current diagnosis of cancer or unresectable cancer that has not been in complete remission for at least 5 years.
  15. Any other clinically relevant abnormal findings that in the opinion of the Investigator or medical monitor might compromise the safety of the patient in the study or interfere with evaluation of the study intervention.
  16. Treatment with marketed or biologics within 4 months or a minimum of 5 half-lives.
  17. Treatment with Systemic within 4 weeks.
  18. Chronic oral or systemic CS use for asthma or for any other indication (with the exception of stable replacement therapy in adrenal insufficiency).
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
537 participants (actual)

Study arms

  • Experimental
    AZD8630 dose A

    Inhaled AZD8630 administered at a dose A

    Drug: AZD8630 · Device: Inhaler

  • Experimental
    AZD8630 dose B

    Inhaled AZD8630 administered at a dose B

    Drug: AZD8630 · Device: Inhaler

  • Experimental
    AZD8630 dose C

    Inhaled AZD8630 administered at a dose C

    Drug: AZD8630 · Device: Inhaler

  • Placebo comparator
    Placebo

    Inhaled placebo

    Drug: Placebo · Device: Inhaler

Interventions

  • The drug will be administered by inhalation

  • DrugPlacebo

    The placebo will be administered by inhalation

  • DeviceInhaler

    The drug/placebo will be administered by inhalation using the inhaler

06

What researchers measure

Primary outcomes

  1. Time to first CompEx Asthma event

    The CompEx Asthma is a composite endpoint for exacerbations that captures asthma-worsening episodes based on combination of diary events (worsening in daily PEF, asthma symptoms and rescue medication use) plus severe asthma exacerbation events. Diary events are defined by threshold and slope criteria using the following morning/evening diary variables: * PEF * Asthma symptom score (0 to 3) * Use of rescue medication

    Time frame: 12 weeks

Secondary outcomes

  1. Pre-BD FEV1

    Change from baseline in pre-bronchodilator forced expiratory volume in 1 second.

    Time frame: 12 weeks

  2. ACQ-6:

    Change from baseline in the Asthma Control Questionnaire 6 (ACQ-6). The ACQ-6 has 6 questions (regarding asthma symptoms and rescue bronchodilator use). Answering the questions results in a score out of 6. A Score of 0 indicates complete control and 6 reflects severely uncontrolled disease

    Time frame: 12 weeks

  3. AQLQ12+

    Change from baseline in the Asthma Quality of Life Questionnaire for 12 Years and Older. The AQLQ12+ includes 32 questions grouped into four domains: symptoms; activity limitations; emotional function; and, environmental stimuli. Each question is scored on a seven-point Likert scale, which ranges from 7 (no impairment) to 1 (severe impairment). The overall score is calculated as the mean of all questions, and the four domain scores are the means of the scores for the questions in the respective domains

    Time frame: 12 weeks

  4. SGRQ

    Change from baseline in the St. George's Respiratory Questionnaire. The SGRQ includes 50 questions grouped into two parts: Part 1 : Symptoms component (frequency \& severity) with a 1, 3 or 12-month recall (best performance with 3- and 12-month recall); Part 2: Activities that cause or are limited by breathlessness; Impact components (social functioning, psychological disturbances resulting from airways disease) refer to current state as the recall.

    Time frame: 12 weeks

  5. FeNO

    Change from baseline to: FeNO: Weeks 1, 2, 4, 8, and 12

    Time frame: 12 weeks

07

Study locations

196 sites
  • Research Site
    Mesa, Arizona 85213, United States
  • Research Site
    Huntington Beach, California 92647, United States
  • Research Site
    La Mesa, California 91942, United States
  • Research Site
    Laguna Niguel, California 92677, United States
  • Research Site
    Lancaster, California 93534, United States
  • Research Site
    Long Beach, California 90815, United States
  • Research Site
    San Jose, California 95117, United States
  • Research Site
    New Haven, Connecticut 06510, United States
  • Research Site
    DeBary, Florida 32713, United States
  • Research Site
    Jacksonville, Florida 32216, United States
  • Research Site
    Jensen Beach, Florida 34957, United States
  • Research Site
    Largo, Florida 33777, United States
  • Research Site
    Miami, Florida 33135, United States
  • Research Site
    Miami Lakes, Florida 33014, United States
  • Research Site
    Tampa, Florida 33607, United States
  • Research Site
    Lilburn, Georgia 30047, United States
  • Research Site
    Savannah, Georgia 31406, United States
  • Research Site
    Chicago, Illinois 60616, United States
  • Research Site
    Winfield, Illinois 60190, United States
  • Research Site
    Ames, Iowa 50010, United States
  • Research Site
    Kansas City, Kansas 66160, United States
  • Research Site
    Baltimore, Maryland 21237, United States
  • Research Site
    Methuen, Massachusetts 01844, United States
  • Research Site
    Ann Arbor, Michigan 48109, United States
  • Research Site
    Detroit, Michigan 48202, United States
  • Research Site
    Las Vegas, Nevada 89102, United States
  • Research Site
    Las Vegas, Nevada 89119, United States
  • Research Site
    Riverdale, New Jersey 07457, United States
  • Research Site
    Middletown, New York 10941, United States
  • Research Site
    Greenville, North Carolina 27834, United States
  • Research Site
    Winston-Salem, North Carolina 27104, United States
  • Research Site
    Beavercreek, Ohio 45431, United States
  • Research Site
    Lima, Ohio 45801, United States
  • Research Site
    Oklahoma City, Oklahoma 73120, United States
  • Research Site
    Horsham, Pennsylvania 19044, United States
  • Research Site
    Austin, Texas 78704, United States
  • Research Site
    McKinney, Texas 75069, United States
  • Research Site
    Mesquite, Texas 75149, United States
  • Research Site
    Pearland, Texas 77584, United States
  • Research Site
    San Antonio, Texas 78215, United States
  • Research Site
    American Fork, Utah 84003, United States
  • Research Site
    Roy, Utah 84067, United States
  • Research Site
    Salt Lake City, Utah 84124, United States
  • Research Site
    Hampton, Virginia 23666, United States
  • Research Site
    Milwaukee, Wisconsin 53228, United States
  • Research Site
    Alberdi, X5033DCE, Argentina
  • Research Site
    CABA, C1426, Argentina
  • Research Site
    Capital Federal, C1060ABN, Argentina
  • Research Site
    Mar del Plata, 7600, Argentina
  • Research Site
    Quilmes, B1878FNR, Argentina
  • Research Site
    Rosario, 2000, Argentina
  • Research Site
    San Fernando, B1646EBJ, Argentina
  • Research Site
    San Juan Bautista, 1888, Argentina
  • Research Site
    San Miguel de Tucumán, 4000, Argentina
  • Research Site
    Duffel, 2570, Belgium
  • Research Site
    Mechelen, 2800, Belgium
  • Research Site
    Namur, 5101, Belgium
  • Research Site
    Chile, 7770484, Chile
  • Research Site
    Curicó, 3341643, Chile
  • Research Site
    Santiago, 7500587, Chile
  • Research Site
    Santiago, 7500691, Chile
  • Research Site
    Talca, 3465584, Chile
  • Research Site
    Viña del Mar, 2540488, Chile
  • Research Site
    Baotou, 014010, China
  • Research Site
    Changchun, 130021, China
  • Research Site
    Chengdu, 610078, China
  • Research Site
    Chongqing, 401320, China
  • Research Site
    Guangzhou, 510163, China
  • Research Site
    Guiyang, 510630, China
  • Research Site
    Hefei, 230061, China
  • Research Site
    Hohhot, 010010, China
  • Research Site
    Jinan, 250021, China
  • Research Site
    Lanzhou, 730000, China
  • Research Site
    Nanchang, 330006, China
  • Research Site
    Ningbo, 315010, China
  • Research Site
    Qingdao, 266011, China
  • Research Site
    Shanghai, 200080, China
  • Research Site
    Shenyang, 110004, China
  • Research Site
    Shijiazhuang, 050051, China
  • Research Site
    Taiyuan, 030032, China
  • Research Site
    Wenzhou, 325027, China
  • Research Site
    Xuzhou, 221000, China
  • Research Site
    Brno, 62500, Czechia
  • Research Site
    Hradec Králové, 50005, Czechia
  • Research Site
    Jindřichův Hradec, 377 01, Czechia
  • Research Site
    Kralupy nad Vltavou, 278 01, Czechia
  • Research Site
    Pilsen, 32300, Czechia
  • Research Site
    Prague, 15300, Czechia
  • Research Site
    Teplice, 415 01, Czechia
  • Research Site
    Varnsdorf, 407 47, Czechia
  • Research Site
    Aalborg, 9100, Denmark
  • Research Site
    Hvidovre, 2650, Denmark
  • Research Site
    København NV, 2400, Denmark
  • Research Site
    Odense, 5000, Denmark
  • Research Site
    Roskilde, 4000, Denmark
  • Research Site
    Vejle, 7100, Denmark
  • Research Site
    Lyon, 69317, France
  • Research Site
    Marseille, 13915, France
  • Research Site
    Nice, F-06002, France
  • Research Site
    Paris, 75018, France

Showing the first 100 of 196 sites across 23 countries. Choose a country and city above to see the rest.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2024 to primary completion in Feb 2026, 17 months.

Of 137 industry-sponsored phase 2 interventional studies under Asthma, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's 17 months is close to that.

Counting every sponsor, half of 199 studies reached it within 20 months; a quarter within 12 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2024
First posted
Jul 31, 2024
StartActual
Aug 30, 2024
Primary completionActual
Feb 4, 2026
CompletionActual
Feb 4, 2026
Last update
Mar 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06529419
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jul 31, 2024
Start date
Aug 30, 2024
Primary completion
Feb 4, 2026
Completion
Feb 4, 2026
Last update
Mar 2, 2026

Study contacts

Njira Lugogo
principal investigator · Univeristy of Michigan Hospital, Ann Arbor, MI, US

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sunakiment

Start the discussion